雜志介紹

Expert Opinion On Investigational Drugs雜志介紹

《Expert Opinion On Investigational Drugs》是一本以English為主的未開放獲取國際優秀期刊，中文名稱研究藥物專家意見，本刊主要出版、報道醫學-PHARMACOLOGY & PHARMACY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為4.9，最新CiteScore 指數為10。

本刊近期中國學者發表的論文主要有：

• Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy

  Author: Zhang, Junmin; Zhang, Juanhong; Leung, Elaine Lai-Han; Yao, Xiao-Jun

• Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled dose-escalation study

  Author: Yan, Diqin; Niu, Suping; Hu, Dingyuan; Dong, Wenliang; Sun, Yunjuan; Wang, Qian; Wang, Simin; Gu, Qun; Liu, Gang; Wang, Jiaxue; Chen, Liming; Lv, Jie; Zheng, Qingshan; Song, Haifeng; Fang, Yi

• Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects

  Author: Wang, Yanli; Xue, Jinling; Su, Zhengjie; Cui, Yingzi; Liu, Guangwen; Yang, Wei; Liu, Zhengzhi; Chen, Jiahui; Ren, Qing; Yu, Shuang; Cheng, Yang; Zhou, Yannan; Wang, Wanhua; Chen, Xuesong; Qu, Dongmei; Deng, Qiaohuan; Zhao, Yicheng; Yang, Haimiao

• The Jakinibs in systemic lupus erythematosus: progress and prospects.

  Author: Mok CC¹.

英文介紹

Expert Opinion On Investigational Drugs雜志英文介紹

Expert Opinion on Investigational Drugs (ISSN 1354-3784 [print], 1744-7658 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on drugs in preclinical and early stage clinical development, providing expert opinion on the scope for future development.

The Editors welcome:

Reviews covering preclinical through to Phase II data on drugs or drug classes for specific indications, and their potential impact on future treatment strategies

Drug Evaluations reviewing the clinical and pharmacological data on a particular drug

Original Research papers reporting the results of clinical investigations on agents that are in Phase I and II clinical trials

The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D.